Wanbury Ltd Reports Strong FY26 Results

Wanbury Ltd has announced its audited financial results for the fiscal year 2026, reporting a significant 116.6% year-on-year increase in Profit After Tax (PAT) to ₹66.1 crore. Earnings Per Share (EPS) for the fiscal year stood at ₹20.55.

Reader Takeaway: Strong profit growth and margin expansion offset Q4 geopolitical revenue impact.

What just happened

Wanbury Ltd's audited financial results for FY26 show a substantial jump in profitability. PAT grew by 116.6% to ₹66.1 crore compared to ₹30.5 crore in FY25. Revenue from operations increased by 8.5% to ₹650.3 crore from ₹599.5 crore.

EBITDA saw a healthy rise of 34.9% to ₹107.7 crore in FY26, with EBITDA margins expanding to 16.5% from 13.2% in the previous year. PAT margin also saw significant improvement, rising by 509 basis points to 10.2%.

In the fourth quarter (Q4 FY26), revenue was ₹164.6 crore, and PAT grew by 7.2% year-on-year to ₹21.7 crore, despite a one-time exceptional charge of ₹3.6 crore related to new labour code implementation.

Why this matters

The significant profit growth and margin expansion highlight Wanbury's improving operational efficiency and pricing power. The company's ability to grow profits at a much faster rate than revenue indicates effective cost management and operational leverage.

Furthermore, successful product development, including the launch of a new Anaesthetic API and approvals for specialty APIs, alongside a strong regulatory compliance record with zero-observation inspections from international bodies, bolsters investor confidence.

The backstory

Wanbury Ltd is a pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company has been focusing on expanding its product portfolio and enhancing its manufacturing capabilities.

Recent investments in capital expenditure (CAPEX) have enabled the company to operationalize new facilities and product lines, such as the Tanuku facility for API production.

What changes now

The strong FY26 performance sets a positive tone for the company. The successful launch of the Anaesthetic API and its dispatches to Europe, along with a pipeline of specialty APIs, are expected to contribute to future growth.

The company's ongoing focus on process optimization and SAP HANA S4 implementation aims to further improve capacity and scalability, potentially driving continued efficiency gains.

Risks to watch

A key concern highlighted is the impact of the West Asia crisis on Q4 FY26 revenue, which disrupted export dispatches in March 2026. This geopolitical event led to a muted revenue performance in the quarter, underscoring the risks associated with international operations.

Investors will also monitor the integration and ramp-up of new products and the company's ability to manage potential supply chain disruptions arising from global events.

Peer comparison

While specific peer financial data for FY26 is not provided in the filing, Wanbury's performance in terms of PAT growth (+116.6%) and EBITDA margin expansion (to 16.5%) appears robust. Companies in the API and formulation space often focus on regulatory approvals, R&D, and export market penetration.

Wanbury's multiple zero-observation inspections from global regulatory bodies like USFDA, MFDS, and ANVISA place it in good standing within the industry.

Context metrics (time-bound)

• FY26 Revenue: ₹650.3 crore (vs. ₹599.5 crore in FY25, +8.5% YoY)
• FY26 EBITDA: ₹107.7 crore (vs. ₹79.8 crore in FY25, +34.9% YoY)
• FY26 PAT: ₹66.1 crore (vs. ₹30.5 crore in FY25, +116.6% YoY)
• FY26 EPS: ₹20.55 (vs. ₹9.32 in FY25, +122% YoY)
• FY26 EBITDA Margin: 16.5% (vs. 13.2% in FY25)
• FY26 PAT Margin: 10.2% (vs. 5.1% in FY25)
• Q4 FY26 Revenue: ₹164.6 crore
• Q4 FY26 PAT: ₹21.7 crore (+7.2% YoY)

What to track next

Investors will be looking for updates on the commercial performance of the new Anaesthetic API in European markets. Performance of its formulations business and continued traction in export markets will be key indicators for FY27.

Monitoring the company's response to any further geopolitical impacts on its export business and continued success in regulatory audits will be crucial.